November 19, 2026 Global Pulse

Veterinary Diagnostics Is Growing Faster Than Human Diagnostics in Some Segments

By Isabelle Fontaine | Senior Analyst, Cross-Sector Equity & Market Intelligence
9 min read

Veterinary diagnostics is expanding at rates that in several sub-segments are outpacing human diagnostics growth, driven by rising pet ownership, increasing willingness of companion animal owners to pursue advanced diagnostics and treatment, and the structural shift of veterinary practice toward evidence-based medicine supported by in-clinic and reference laboratory testing. The convergence of human diagnostic technology platforms with veterinary applications, the emergence of companion-animal-specific point-of-care instruments, and the growth of specialty veterinary referral centres with imaging suites comparable to community hospital facilities are collectively reshaping a market that was long viewed as a lower-priority extension of the human diagnostics industry.

Pet Humanisation and Its Diagnostic Spending Consequences

The demographic and cultural shift toward treating companion animals as family members, a trend documented across surveys in North America, Western Europe, Australia, and increasingly in urban Asia, has fundamentally altered the economic calculus of veterinary care decisions. Pet owners who would previously have declined diagnostic workups for pets on cost grounds are increasingly willing to authorise blood chemistry panels, urinalysis, imaging studies, and specialist referrals at cost levels that approach or exceed what human insurance would cover for comparable human tests. The willingness to spend reflects both emotional attachment and the broader normalisation of pet health insurance, which is growing in penetration across developed markets and shifting the out-of-pocket cost calculation for individual diagnostic decisions.

The veterinary diagnostics market has historically been dominated by reference laboratory services, where veterinary practices collect samples and ship them to centralised testing facilities for analysis. National Veterinary Laboratory, Antech Diagnostics (a division of Mars Petcare), and IDEXX Laboratories' reference laboratory network have competed for this reference business, which provides broad test menus, high throughput, and established quality systems. The reference laboratory model remains the backbone of veterinary diagnostics for complex or low-volume tests, but the in-clinic point-of-care testing market has been the faster-growing segment as instrument miniaturisation has brought clinically meaningful blood chemistry, haematology, immunoassay, and urinalysis testing capability into the practice environment at acceptable capital cost and turnaround time.

IDEXX Laboratories has been the most commercially successful company in veterinary in-clinic diagnostics, building an installed base of Catalyst chemistry analysers, ProCyte haematology instruments, and SNAP immunoassay platforms across tens of thousands of veterinary practices globally. The company's subscription-based instrument placement model, where practices receive instruments at low or zero upfront cost in exchange for consumable purchase commitments, has created a recurring revenue model with high switching costs that has proven highly defensible against competitor instruments from Zoetis, Heska, and Woodley Equipment. The in-clinic testing revenue model aligns with veterinary practice economics by enabling same-appointment results that improve diagnostic efficiency and client communication.

Imaging Technology in Veterinary Practice

Veterinary imaging has followed human imaging technology with a lag of roughly five to ten years as equipment costs decline to levels appropriate for the veterinary market and as veterinary specialists develop the clinical training to interpret advanced imaging modalities. Digital radiography replaced film-based radiography in most progressive veterinary practices through the 2010s. Ultrasound has become standard equipment in general practice for abdominal and cardiac assessment. Computed tomography and magnetic resonance imaging, once available only at veterinary teaching hospitals, are now deployed at specialty and emergency referral centres across major metropolitan areas, with some practices now offering CT capability as a differentiating service within general practice settings.

The economics of veterinary CT and MRI have been enabled by the emergence of refurbished and veterinary-specific imaging equipment that is priced for practice economics rather than hospital capital budgets. Sound-Eklin, now part of Heliogen, Hallmarq Veterinary Imaging, and several equipment distributors have developed the veterinary imaging market with equipment configurations optimised for animal patient dimensions and veterinary workflow. Hallmarq's standing MRI for horses is a specialised example of veterinary-specific imaging development where human MRI equipment cannot serve the clinical need and purpose-built veterinary solutions have created a distinct market segment.

Dental radiography in companion animal practice has grown significantly as awareness of periodontal disease as a systemic health factor in dogs and cats has increased among pet owners and veterinary practitioners. Companion animal dental radiography systems from Midmark, Dental-Eye, and Progeny Imaging (now Carestream) have found growing markets in both dedicated veterinary dental practices and general practices adding dental imaging capability. The periodontal disease connection to cardiac, renal, and hepatic disease creates a clinical rationale for dental diagnostics that supports owner acceptance of the diagnostic cost.

Companion Animal Genomics and Specialty Testing

Companion animal genetic testing has emerged as a commercially significant segment within veterinary diagnostics, with consumer-facing DNA tests from Embark Veterinary, Wisdom Panel (now a Kinship brand, itself a Mars Petcare company), and DNA My Dog providing breed identification, genetic disease screening, and trait analysis for dog and cat owners. The consumer segment differs from the clinical segment, where breed-associated genetic disease screening informs breeding decisions for pedigree animals and veterinary practitioners use genetic testing to guide clinical management of animals with suspected hereditary conditions.

Orthopedic Foundation for Animals and veterinary genetic testing laboratories including UC Davis Veterinary Genetics Laboratory and GenSol Diagnostics provide clinical-grade genetic testing panels covering conditions including hip and elbow dysplasia genetic markers, progressive retinal atrophy mutations, dilated cardiomyopathy-associated variants, and drug metabolism polymorphisms such as MDR1 mutations that affect anaesthetic and pharmaceutical management. The clinical application of genomic information in veterinary practice is earlier in its development than human clinical genomics but is advancing as testing costs decline and clinical interpretation tools improve.

Veterinary oncology diagnostics has followed the human oncology diagnostics trajectory toward liquid biopsy and molecular characterisation, with companies including PetDx launching OncoK9, a blood-based multi-cancer detection test for dogs, and Volition developing canine cancer biomarker tests. The companion animal cancer diagnostics market benefits from the dog's relatively high cancer incidence, the owner willingness to pursue oncology workup and treatment, and the shorter regulatory pathway for veterinary diagnostic tests compared with human IVD regulation. Data from companion animal cancer diagnostics programs also contributes to comparative oncology research relevant to human cancer biology.

Market Structure and Growth Drivers

The veterinary diagnostics market is consolidating around a small number of large platforms, with IDEXX Laboratories and Zoetis holding dominant positions in in-clinic and reference diagnostics respectively, alongside Mars Petcare's Antech and Kindred Bio in selected segments. The consolidation reflects the same installed base and switching cost economics that characterise human diagnostics, where instrument placements create recurring consumable revenue streams that are highly predictable and difficult to displace once embedded in practice workflow. Independent veterinary diagnostic laboratories are under consolidation pressure from the same forces affecting independent human diagnostic labs, with scale economies in quality systems, logistics, and test menu breadth favouring larger networks.

Veterinary practice consolidation itself is a driver of diagnostic market development. Corporate veterinary practice groups including CVS Group, IVC Evidensia, and VCA (a Mars Petcare company) have standardised diagnostic protocols across their practice networks in ways that accelerate adoption of preferred diagnostic platforms and create volume leverage in supplier negotiations. Independent practices, which still represent the majority of veterinary practice locations in most markets, are increasingly adopting diagnostic protocols influenced by industry guidelines from organisations including the American Animal Hospital Association and the European Society of Veterinary Internal Medicine, which recommend proactive diagnostic screening for chronic conditions in senior animals.

Emerging markets including Brazil, China, and India are showing early-stage veterinary diagnostics growth as companion animal ownership expands in urban middle-class populations and veterinary practice quality improves toward international standards. The penetration of pet insurance and the development of specialty veterinary referral infrastructure in these markets will be key determinants of diagnostic market growth rates outside the established Western markets where current industry economics are most fully developed.

Top 10 Companies in Veterinary Diagnostics

  1. IDEXX Laboratories -- The dominant in-clinic veterinary diagnostics company globally, with Catalyst chemistry analysers, ProCyte haematology instruments, and SNAP rapid immunoassay platforms installed across tens of thousands of practices
  2. Zoetis -- Global animal health leader with veterinary diagnostics operations spanning reference laboratory services, point-of-care testing platforms, and companion animal genomic testing through its Vetscan and genomics portfolios
  3. Antech Diagnostics -- Mars Petcare veterinary reference laboratory network operating across North America and internationally, providing comprehensive test menus for companion and large animal clinical cases
  4. Heska -- Veterinary diagnostics company focused on point-of-care blood testing instruments and allergy testing for companion animals, competing with IDEXX in the in-clinic analyser segment
  5. Embark Veterinary -- Leading canine DNA testing company providing breed identification, genetic disease screening, and trait analysis for dog owners and breeders through direct-to-consumer and veterinary channels
  6. PetDx -- Developer of OncoK9, a blood-based multi-cancer detection test for dogs, applying liquid biopsy technology to companion animal oncology diagnostics
  7. Hallmarq Veterinary Imaging -- UK-based developer of standing equine MRI systems and companion animal MRI solutions purpose-built for veterinary anatomy and clinical workflow requirements
  8. Wisdom Panel -- Kinship (Mars Petcare) brand providing dog and cat DNA testing for breed identification and genetic health screening, with one of the largest companion animal genetic databases globally
  9. Midmark -- Veterinary and human healthcare equipment manufacturer with veterinary dental radiography systems and practice workflow equipment for companion animal dental diagnostics
  10. Sound Veterinary Imaging -- Veterinary imaging company supplying digital radiography, ultrasound, and CT systems to companion animal and equine practices across North America and international markets

Our Take: Veterinary diagnostics is one of the more structurally attractive segments within the broader diagnostics industry, combining the secular tailwind of pet humanisation with the installed base economics and switching cost dynamics that characterise the most defensible human diagnostics franchises. IDEXX's dominant position reflects years of instrument placement investment that is now harvesting recurring consumable revenue, and the competitive moat is durable. The growth vectors in companion animal genomics, oncology liquid biopsy, and advanced imaging represent the next phase of market expansion that will determine which companies extend their positions beyond the current in-clinic chemistry and immunoassay installed base. For investors, this is a market worth monitoring for the depth of its growth runway relative to the demographic drivers underlying it.

Back to All Insights
×